Fair

Anyway, we'll get to that with Virginia's Honey Badger, Senator Amanda Chase.

And also in hour number two, we'll be talking with Hannah Davis from FAIR on immigration.

Stay with The Schilling Show.

Well, thank you, Dr. Turner.

Lots going on in the world of immigration.

And most of it is good news.

You know, for years we talked with FAIR, with Bob and Ira and various other people, and it was always bad news.

I mean, the things that we've got to watch these days, but we have been winning the war, or at least the battle.

cash flowing businesses that are more mature, they're 10 years in and there's some synergies associated with it.

The two deals we've done since the take private with FAIR and now with Humada are a very different archetype and a different persona of entity that is really about accelerating our R&D roadmap aggregating access to clinical data and intelligence that on the front end can power not just one modular component like off, but a broader section of our end to end offering and then unlock the downstream ability to reduce denial.

So the first piece that we went after was we saw there are a lot of companies that were attacking the CDI space, you know, flashback, you know, two, three years ago with a lot of groups raising money, some consolidation in that space.

And we recognized we needed a pre-bill architecture to go after the clinical documentation improvement and then pull forward in that instance a lot of the downstream findings.

You think about the complexity of inpatient claims.

So all of this, you know, ties together in, you know, kind of that overall objective of comprehensively automating parts of the rev cycle.

So we added FAIR, which has been a phenomenal addition.

The team came out of Google's DeepMind project and bring a lot of AI native expertise.